Clinical Trial

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

Study acronym: JYP0322
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 14, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-11-09; most recent amendment 2025-07-09.
Trial Details
NCT Number NCT06128148
Lead Sponsor Guangzhou JOYO Pharma Co., Ltd
Conditions Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Neoplasms, Brain Neoplasms
Enrollment 101 participants
Start Date 2022-05-04
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-14